Use of Neboglamine in the Treatment of Toxicodependency

Abstract

Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.

1 . Use of neboglamine, (S)-4-amino-N(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs. 
   
   
       2 . Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the therapeutic treatment of drug-induced abstinence crises. 
   
   
       3 . Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapeutic treatment of drug-induced tolerance phenomena. 
   
   
       4 . Use according to any of  claim 1 , wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of the active substances. 
   
   
       5 . The use according to  claim 1 , wherein neboglamine is administered in a therapeutically effective amount of from 10 to 600 mg/day. 
   
   
       6 . The use according to  claim 1 , wherein neboglamine is administered in a therapeutically effective amount of from 30 to 300 mg/day. 
   
   
       7 . The use according to  claim 1 , wherein said drug is a CNS sedative, a stimulant or a hallucinogen. 
   
   
       8 . The use according to  claim 7 , wherein said CNS sedative is selected from opiates, barbiturates, benzodiazepines and alcohol. 
   
   
       9 . The use according to  claim 7 , wherein said stimulants are selected from amphetamines and cocaine. 
   
   
       10 . The use according to  claim 7 , wherein said hallucinogens are selected from LSD, mescaline, cannabis (marijuana) or phencyclidine. 
   
   
       11 . Use according to  claim 2 , wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances. 
   
   
       12 . Use according to  claim 3 , wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances.